AlphAIAlphAI — Financial news for AI agents
investing.comNOV 31 min read$MDGL

Madrigal Pharmaceuticals earnings beat by $2.66, revenue topped estimates

Madrigal Pharmaceuticals (MDGL) reported Q3 EPS of $1.83, beating estimates by $2.66, with revenue of $431.3M, exceeding expectations of $405.27M. The stock closed at $431.16, down 15.47% over 3 months and 3.03% over 12 months. InvestingPro rates its financial health as 'good performance'.

Original reporting
investing.com
Published Nov 3, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MDGL
Bullish
high confidence
Mentioned
$MDGL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDGLBullishMed
01

Why it matters

The earnings surprise could trigger short‑term buying interest, but lack of forward guidance tempers the upside.

02

Market read

Earnings beat is the primary catalyst for potential price movement in MDGL.

03

What to watch

No guidance was provided; future revenue trajectory remains uncertain.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Madrigal Pharmaceuticals (NASDAQ: MDGL) is a biotech focused on rare diseases. The article provides its latest quarterly earnings results.

Company-level read

Ticker impact

$MDGLBullishHigh confidence
Context

Madrigal Pharmaceuticals reported Q3 EPS of $1.83, beating estimates by $2.66 and revenue of $431.3M versus $405.27M consensus.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

The surprise EPS beat and revenue beat are fresh primary disclosures that can move the stock in the near term.

Market effects

Sector

Positive earnings may lift other biotech and specialty pharma peers.

Regional

Limited to US biotech sector.

Global

Minor, confined to investors tracking small‑cap pharma earnings.

Counterpoint

What could challenge this read

The beat may already be priced in; caution on potential pull‑back if guidance is weak.

Key entities

  • company
    Madrigal Pharmaceuticals

    Biotech firm reporting Q3 results.

Read at source← All news

StoryMadrigal Pharmaceuticals posts Q3 2026 earnings beat, shares jump double‑digits

Also covered by

5 outlets

Related articles

NOV 3
$MDGLMed

Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50%

Madrigal Pharmaceuticals (MDGL) reported a Q3 profit of $55.44M, reversing a year-earlier loss, driven by a 50% sales increase of Rezdiffra to $431.30M. R&D expenses declined, while SG&A and cost of sales rose. Over 55,850 patients are now using Rezdiffra, and the company plans a Phase 3 trial for MASH cirrhosis in 2027. MDGL stock is up 9.89%.

rttnews.com2 min
NOV 3
$MDGLHigh

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates • Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability • Rezdif

SEC EDGAR 8-K3 min
NOV 3
$MDGLHighAI 9/10

Why is Madrigal Pharmaceuticals stock surging today?

Madrigal Pharmaceuticals stock surged 14.1% to $491.90 after Q3 2026 results beat expectations, with adjusted earnings of $1.83 per share and revenue of $431.3 million. Rezdiffra, the company's flagship drug, drove revenue growth and achieved blockbuster status. CEO Bill Sibold highlighted continued demand and market growth. The company also announced a new clinical trial. Analysts had a positive outlook before the report.

investing.com2 min
NOV 3
$MDGLMedAI 8/10

Madrigal: Q3 Earnings Snapshot

Madrigal Pharmaceuticals (MDGL) reported Q3 earnings of $55.4M, or $1.83 per share, exceeding analyst expectations of a $1.09 per share loss. Revenue was $431.3M, surpassing the $400M forecast.

finance.yahoo.com2 min